advertisement
Reply
 
Thread Tools Display Modes
Old 04-18-2007, 05:20 PM #1
MelodyL's Avatar
MelodyL MelodyL is offline
Wise Elder
 
Join Date: Aug 2006
Posts: 8,292
15 yr Member
MelodyL MelodyL is offline
Wise Elder
MelodyL's Avatar
 
Join Date: Aug 2006
Posts: 8,292
15 yr Member
Default Zenvia??????

Anybody know anything about this drug??? Sorry, if this has been answered before but with my senior moments lately, who remembers anything?? lol
I copied and pasted the following


AVANIR Announces Last Patient Enrolled in Neuropathic Pain Phase III Trial with Zenvia
Posted: 11/14/2006 @ 3:06 PM

AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that the Company has enrolled the targeted number of patients needed to assess the efficacy endpoint in its ongoing Zenvia Phase III painful diabetic neuropathy trial.

The protocol for the Phase III study was reviewed by the U.S. Food and Drug Administration (FDA) through a special protocol assessment (SPA) process. An SPA is an agreement between the FDA and the sponsor of a clinical trial documenting that if the study endpoints are met, the results should be acceptable to support a New Drug Application (NDA). Assuming positive outcomes, AVANIR currently expects to use the data from this study as one of the pivotal Phase III clinical trials required before it would be able to submit an NDA for this indication.

“In the statistical plan, a total of 364 patients would be required to obtain 90% power with a 30% allowance for drop out,” said Randall Kaye M.D., Vice President of Clinical and Medical Affairs for AVANIR “We have determined that it is unnecessary to enroll additional patients and now consider the trial fully enrolled with approximately 380 patients. The data from the trial is currently anticipated in mid-2007.”

Painful diabetic neuropathy may affect more than 50% of patients with diabetes as their disease progresses, according to the American Diabetes Association. The damaged nerves can alter the sensitivity of pain centers in the spinal cord and consequently intensify pain transmission within the central nervous system. Symptoms of painful diabetic neuropathy may include numbness or insensitivity to pain or temperature, a tingling, burning, or prickling sensation, sharp pains or cramps, extreme sensitivity to touch, and loss of balance and coordination.

About AVANIR

AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR’s products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. AVANIR currently markets FazaClo®, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenic or schizoaffective disorder. For full prescribing information and important safety information regarding FazaClo, please visit www.fazaclo.com. Zenvia, AVANIR's lead product candidate for the treatment of involuntary emotional expression disorder (IEED), is the subject of an approvable letter from the FDA and future development plans for this product candidate are under consideration. The Company does not know at this time what impact, if any, the ongoing discussions with the FDA for IEED may have on the development of Zenvia for other indications. Additionally, AVANIR has completed the patient recruitment in a Phase III clinical trial with Zenvia as a potential treatment for patients with painful diabetic neuropathy. AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease. The Company's first commercialized product, abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

--------------------------------------------------------------------------------
__________________

.


CONSUMER REPORTER
SPROUT-LADY



.
MelodyL is offline   Reply With QuoteReply With Quote

advertisement
Old 04-18-2007, 06:19 PM #2
mrsD's Avatar
mrsD mrsD is offline
Wisest Elder Ever
 
Join Date: Aug 2006
Location: Great Lakes
Posts: 33,508
15 yr Member
mrsD mrsD is offline
Wisest Elder Ever
mrsD's Avatar
 
Join Date: Aug 2006
Location: Great Lakes
Posts: 33,508
15 yr Member
Post more...

Don't expect to see it soon:
Quote:
Avanir slashes jobs, puts Zenvia on ice
November 10, 2006

Hammered by the FDA's demand for more data on Zenvia, an experimental drug for involuntary emotional expression disorder (IEED), Avanir Pharmaceuticals has halted commercial development of the drug and cut its workforce by 16 percent. Avanir's stock price has plunged about 80 percent this year, and company officials said they were cutting their burn rate to $10 million a quarter.

"These cost reduction actions and the recently announced financing will provide financial flexibility for the company while determining the future opportunity for Zenvia," said Eric K. Brandt, CEO of Avanir. "We believe in the therapeutic potential of Zenvia to provide relief for this unmet medical condition. I have personally had the pleasure of talking to IEED patients and their caregivers about the life-changing effect the drug candidate Zenvia has had on patients' lives in our clinical trials. We will provide an update on this program once we process the feedback from our planned meeting with the FDA."

- see the release on Avanir's restructuring
This is pretty confusing: Two names same drug:
http://www.associatedcontent.com/art...different.html

About Zenvia:
Quote:
About Zenvia

Zenvia is a combination of two well-characterized compounds, the active ingredient dextromethorphan, and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. The first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways, through presynaptic inhibition of glutamate release via sigma-1 receptor agonist activity, and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity.
It is only dextromethorphan... DM found in cough preps in this country. Some studies show high dose DM might help PN but
results are conflicted. I believe Nide44 tried it without success.
__________________
All truths are easy to understand once they are discovered; the point is to discover them.-- Galileo Galilei

************************************

.
Weezie looking at petunias 8.25.2017


****************************
These forums are for mutual support and information sharing only. The forums are not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. Always consult your doctor before trying anything you read here.
mrsD is offline   Reply With QuoteReply With Quote
Old 04-18-2007, 06:48 PM #3
MelodyL's Avatar
MelodyL MelodyL is offline
Wise Elder
 
Join Date: Aug 2006
Posts: 8,292
15 yr Member
MelodyL MelodyL is offline
Wise Elder
MelodyL's Avatar
 
Join Date: Aug 2006
Posts: 8,292
15 yr Member
Default

Wow, thanks a lot for the information.

And what exactly is "involuntary emotional expression disorder" ??? I know it has something to do with brain injuries, right??

melody
__________________

.


CONSUMER REPORTER
SPROUT-LADY



.
MelodyL is offline   Reply With QuoteReply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off



All times are GMT -5. The time now is 06:47 AM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.